FibroGen

^{Priced, Nasdaq: FGEN}

Developing therapies for anemia and fibrosis; backed by Astellas and AstraZeneca

Industry: Health Care

First Day Return: +22.2%

FGEN

Developing therapies for anemia and fibrosis; backed by Astellas and AstraZeneca

IPO News for FibroGen

US IPO Weekly Recap: Virgin America flies high as IPO market reaches 250 with 9 new offerings 11/14/14
Feeling anemic? Biotech FibroGen prices IPO at $18, toward the top of the range 11/13/14
Week ahead: 10 US IPOs planned for the week of Nov 10 as IPO market hits 250 with Virgin America 11/09/14

IPO Data
IPO Date	11/13/2014
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$146
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.FibroGen.com
Headquarters	San Francisco, CA, United States
Founded	1993
Employees at IPO	337

IPO News for FibroGen

FibroGen (FGEN) Performance